Remove 2005 Remove Drug Development Remove Pharmaceutical Companies
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

4,6 Five patent issues that European biosimilar developers should consider before entering the US market Quality control of the botanical drug substances was one of the critical factors that led to barricades during the development of Veregen and Mytesi. 2005 [cited 2024May]. 2012/1916). BMB Reports. 2017;50(3):111–6.

article thumbnail

STAT+: Report: Tuberculosis R&D funding is up, but still short of goals and dominated by a few players

STAT

Although research and development funding for tuberculosis reached new heights last year, the total fell substantially short of goals set by the United Nations and most of the increase came from just two organizations, according to a new report. Just 9% came from the private sector, such as pharmaceutical companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Beating the Big C

Pharmaceutical Technology

The world’s biggest pharmaceutical company Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. ” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.”

article thumbnail

Patents: a necessary evil?

European Pharmaceutical Review

Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment. 2020-02-24.

article thumbnail

Investment fuels AI-driven development of breakthrough genomic medicines

pharmaphorum

“We founded Whitelab Genomics after realising the potential to use data, data science, and AI in a more systematic way to develop genomic therapies,” Del Bourgo says. Del Bourgo sees Debiopharm’s pharmaceutical industry expertise as an asset to the start-up as it expands its partnerships with new and international customers. “In

article thumbnail

A history of AstraZeneca

pharmaphorum

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

Vaccines 116
article thumbnail

The next frontier: Global leadership in biopharma

Express Pharma

She also suggests, “India can foster collaboration between the IT and the biopharma companies through government or private initiated collaborative channels – these can help facilitate discussions around latest technological advancements available that could help in overcoming challenges in biopharma drug development and advancement.”